

REMARKS

In response to the Restriction Requirement dated September 15, 2000, applicants elected group I (claims 1-5, and 6,7) directed to a method of inhibiting an undesirable immune associated reaction, and as a species, MHC Class I molecules.

Applicants note that claims 6 and 7 are directed to both a method and an antibody. However, in the Restriction Requirement, claims directed to a method were restricted to Group I and claims directed to an antibody were restricted to Group II. Accordingly, applicants have now amended the claims to more particularly claim the elected invention. Claim 6 has been canceled, and claim 7 as amended is directed to a method of inhibiting an undesirable immune associated reaction.


Attached hereto is an Appendix showing the changes made to claim 7.

In view of the foregoing, applicants respectfully submit that all claims are now in condition for allowance. Early and favorable action is requested.

In the event that any additional fees are required, the PTO is authorized to charge our deposit account No. 50-0850.

Respectfully submitted,

Date: 3/25/01


Ronald I. Eisenstein
(Reg. No.: 30,628)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6054

APPENDIX

The changes made by the amendments to the claims are shown below with insertions being underlined and deletions being bracketed.

7. (Amended) [The antibody of claim 6] The method of claim 1, wherein said antibody binds to [one of the group of MHC components] an MHC Class I component selected from the group consisting of [X chains of the] MHC Class I a chains, β 2 microglobulin, calnexin, transporter associated with antigen processing (TAP) and tapasin.